The cerebrospinal fluid (CSF) biomarker phosphorylated tau/amyloid-β 1-42 (pTau/Aβ42) is recognized as having a strong concordance with amyloid-PET status, as well as a clinical robustness that would favor its routine clinical use. Henrik Schinke, PhD, Roche Diagnostics Europe, Penzberg, Germany, discusses some of the properties of pTau/Aβ42 that make it applicable to the clinic, including its robustness and cost-effectiveness compared to PET scans. The Elecsys® CSF pTau181 and Aβ42 assays are already available in 45 countries and recently received approval from the US Food and Drug Administration (FDA) for their use in the US. This interview took place at the Clinical Trials on Alzheimer’s Disease Congress 2022 in San Francisco.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.